Treatment with the bisphosphonate zoledronate appears to reduce the incidence of fragility fractures with minimal use of calcium supplements in women with hip bone mineral density characterized as osteopenia, according to the results of a 6-year trial.
Adding fenofibrate to allopurinol or febuxostat reduces uric acid levels in patients with gout without showing any significant change in renal or hepatic functions, a recent study has shown. This suggests that cotreatment of fenofibrate with xanthine oxidase inhibitors is a reasonable option for treating gout in patients who have high triglyceride levels.
Women with silicone breast implants are at heightened risk of subsequently developing an autoimmune/rheumatic disorder, specifically sarcoidosis, systemic sclerosis and Sjögren’s syndrome, according to a study.
Low-dose methotrexate, which is approved for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders, has shown unexpectedly disappointing results in preventing cardiovascular (CV) events among patients with a prior myocardial infarction (MI) or multivessel coronary disease, according to CIRT*, potentially ruling out what could be an affordable option for treating inflammation related to atherosclerosis.
Ixekizumab is safe and effective in the treatment of patients with active radiographic axial spondyloarthritis and previously inadequate response or intolerance to tumour necrosis factor inhibitors, producing rapid and significant improvements in the signs and symptoms, according to the 16-week results of the phase III COAST-W trial.
In utero exposure to hydroxychloroquine (HCQ) appears to reduce the risk of developing cutaneous neonatal lupus erythematosus, as shown in a multicentre case-control study. Moreover, there is a trend toward delayed rash onset in HCQ-exposed infants with cNL.
The addition of ustekinumab to standard-of-care (SOC) treatment resulted in improved outcomes in adults with systemic lupus erythematosus (SLE) whose disease activity persisted despite standard treatment, according to a phase II trial.
The question of whether to exercise or not typically emerges in the setting of chronic pain, as patients fear that moving may contribute to exacerbate their condition. Yet, exercise does exert hypoalgesic effects on chronic pain conditions however variable these effects are, according to a senior physiotherapist who spoke at the Singapore Health & Biomedical Congress 2018.
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Compelling evidence indicates weight bias, in which obese students appear to do less well in tertiary education than their healthy weight peers, according to a systematic review. University/college attainment appears to be less impacted by socioeconomic factors than school-based achievement.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.